ReP USP - Resultado da busca

Artigo de periodico
Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial (2017)
Mehta, Sanjay; Sastry, Bhagavatula Kutumba Srinivasa; Souza, Rogério; Torbicki, Adam; Ghofrani, Hossein-Ardeschir; Channick, Richard N.; Delcroix, Marion; Pulido, Tomás; Simonneau, Gérald; Wlodarczyk, John; Rubin, Lewis J.; Jansa, Pavel; Hunsche, Elke; Galiè, Nazzareno; Perchenet, Loïc; Sitbon, Olivier
Fonte: CHEST. Unidade: FM
Assuntos: HIPERTENSÃO PULMONAR, QUALIDADE DE VIDA, FARMACOTERAPIA, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MEHTA, Sanjay et al. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. CHEST, v. 151, n. 1, p. 106-118, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.chest.2016.08.1473. Acesso em: 24 out. 2025.
APA
Mehta, S., Sastry, B. K. S., Souza, R., Torbicki, A., Ghofrani, H. -A., Channick, R. N., et al. (2017). Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. CHEST, 151( 1), 106-118. doi:10.1016/j.chest.2016.08.1473
NLM
Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani H-A, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial [Internet]. CHEST. 2017 ; 151( 1): 106-118.[citado 2025 out. 24 ] Available from: https://doi.org/10.1016/j.chest.2016.08.1473
Vancouver
Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani H-A, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial [Internet]. CHEST. 2017 ; 151( 1): 106-118.[citado 2025 out. 24 ] Available from: https://doi.org/10.1016/j.chest.2016.08.1473
Artigo de periodico
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension (2017)
Galiè, Nazzareno; Jansa, Pavel; Pulido, Tomás; Channick Richard N.; Delcroix, Marion; Ghofrani, Hossein-Ardeschir; Le Brun, Franck-Olivier; Mehta, Sanjay; Perchenet, Loïc; Rubin Lewis J.; Sastry, B.K.S.; Simonneau, Gérald; Sitbon, Olivier; Souza, Rogério; Torbicki, Adam
Fonte: European Heart Journal. Unidade: FM
Assuntos: MORTALIDADE, CATETERISMO CARDÍACO, ESTUDOS RANDOMIZADOS, HIPERTENSÃO PULMONAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GALIÈ, Nazzareno et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, v. 38, n. 15, p. 1147-1155, 2017Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehx025. Acesso em: 24 out. 2025.
APA
Galiè, N., Jansa, P., Pulido, T., Channick Richard N.,, Delcroix, M., Ghofrani, H. -A., et al. (2017). SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 38( 15), 1147-1155. doi:10.1093/eurheartj/ehx025
NLM
Galiè N, Jansa P, Pulido T, Channick Richard N., Delcroix M, Ghofrani H-A, Le Brun F-O, Mehta S, Perchenet L, Rubin Lewis J., Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension [Internet]. European Heart Journal. 2017 ; 38( 15): 1147-1155.[citado 2025 out. 24 ] Available from: https://doi.org/10.1093/eurheartj/ehx025
Vancouver
Galiè N, Jansa P, Pulido T, Channick Richard N., Delcroix M, Ghofrani H-A, Le Brun F-O, Mehta S, Perchenet L, Rubin Lewis J., Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension [Internet]. European Heart Journal. 2017 ; 38( 15): 1147-1155.[citado 2025 out. 24 ] Available from: https://doi.org/10.1093/eurheartj/ehx025
Artigo de periodico
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension (2013)
Pulido, Tomás; Adzerikho, Igor; Channick, Richard N.; Delcroix, Marion; Galiè, Nazzareno; Ghofrani, Hossein-Ardeschir; Jansa, Pavel; Jing, Zhi-Cheng; Le Brun, Franck-Olivier; Mehta, Sanjay; Mittelholzer, Camilla M.; Perchenet, Loïc; Sastry, B. K. S.; Sitbon, Olivier; Souza, Rogério; Torbicki, Adam; Zeng, Xiaofeng; Rubin, Lewis J.; Simonneau, Gérald
Fonte: The New England Journal of Medicine. Unidade: FM
Assuntos: HIPERTENSÃO PULMONAR (MORTALIDADE), CATETERISMO CARDÍACO, CONDUTAS TERAPÊUTICAS, MEDICAMENTO (EFEITOS ADVERSOS), MÉTODO DUPLO-CEGO, PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PULIDO, Tomás et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. The New England Journal of Medicine, v. 369, n. 9, p. 809-818, 2013Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1213917. Acesso em: 24 out. 2025.
APA
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H. -A., et al. (2013). Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. The New England Journal of Medicine, 369( 9), 809-818. doi:10.1056/NEJMoa1213917
NLM
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Jing Z-C, Le Brun F-O, Mehta S, Mittelholzer CM, Perchenet L, Sastry BKS, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension [Internet]. The New England Journal of Medicine. 2013 ; 369( 9): 809-818.[citado 2025 out. 24 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1213917
Vancouver
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Jing Z-C, Le Brun F-O, Mehta S, Mittelholzer CM, Perchenet L, Sastry BKS, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension [Internet]. The New England Journal of Medicine. 2013 ; 369( 9): 809-818.[citado 2025 out. 24 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1213917

Unidades USP

ReP

Filtros

Autores

Assuntos

Indexado em

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos